Stock TSHA TAYSHA GENE THERAPIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Taysha Gene Therapies, Inc.

Equities

TSHA

US8776191061

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-02 pm EDT 		5-day change 1st Jan Change
2.16 USD -4.42% Intraday chart for Taysha Gene Therapies, Inc. -12.37% +22.03%
Jul. 01 Taysha Gene Therapies Insider Bought Shares Worth $2,999,999, According to a Recent SEC Filing MT
Jul. 01 Piper Sandler Cuts Price Target on Taysha Gene Therapies to $7 From $9, Maintains Overweight Rating MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
AQ
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
AQ
TSHA 102 in clinical evaluation for Rett syndrome: Cohort one data from the REVEAL Phase 1/2 Adolescent Adult and Pediatric trials
PU
Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome
AQ
Taysha Gene Therapies to Present Clinical Data from Both REVEAL Phase 1/2 Trials During Company-Hosted Webcast and at 2024 IRSF Rett Syndrome Scientific Meeting
AQ
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update
AQ
Taysha Gene Therapies to Release First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 14
AQ
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome
AQ
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates
AQ
Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19
AQ
Taysha Gene Therapies : March 2024 Corporate Presentation
PU
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome
AQ
Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs
AQ
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
Taysha Gene Therapies Announces Poster Presentation on TSHA-102 in Rett Syndrome at Upcoming British Paediatric Neurology Association 2024 Annual Conference
AQ
Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TSHA Stock
  4. News Taysha Gene Therapies, Inc.
  5. Press Releases